Search results for "Hospital"

showing 10 items of 2264 documents

A Balancing Act-How Mental Health Professionals Experience Being Personal in Their Relationships with Service Users.

2017

Although being personal in relationships with service users is commonly described as an important aspect of the way that professionals help people with severe mental problems, this has also been described to bring with it a need to keep a distance and set boundaries.This study aims to explore how professionals working in psychiatric care view being personal in their relationships with users.Qualitative interviews with 21 professionals working in three outpatient psychiatric units, analyzed through thematic analysis.Being personal in their relationships with users was described as something that participants regarded to be helpful, but that also entails risks. Participants described how they…

Occupational therapyAdultMalePsychiatric aidesmedicine.medical_specialtyAttitude of Health PersonnelPsychiatric AidesMEDLINEPsychiatric Department Hospital03 medical and health sciences0302 clinical medicineAmbulatory careNursingAmbulatory CareMedicineHumansService user030212 general & internal medicineQualitative ResearchAgedbusiness.industryMental DisordersProfessional-Patient RelationsMiddle AgedMental health030227 psychiatryFemalePersonal experiencePshychiatric Mental HealthbusinessQualitative researchIssues in mental health nursing
researchProduct

Quality of Occupational Therapy Services in the Ergotherapy Department of the “Dr. Gh. Preda” Psychiatric Hospital of Sibiu

2020

Abstract The patients with psychiatric pathology, during the hospitalization in the “Dr.Gh.Preda” Psychiatric Hospital of Sibiu attend to the activities carried out in the ergotherapy department. The complementary therapies are designed to help the patient to integrate socially and professionally easier. To make this possible, the quality of the services provided to the patients is important. We conducted this study in order to evaluate the quality of these services and to find solutions for possible problems. Occupational therapy has had an important place in the history of our hospital, being a department with tradition in which the quality of the services offered has always been emphasiz…

Occupational therapymedicine.medical_specialtyErgotherapybusiness.industrymedia_common.quotation_subjectFamily medicinemedicinePsychiatric hospitalQuality (business)General Medicinebusinesshumanitiesmedia_commonActa Medica Transilvanica
researchProduct

Fear of cancer progression in patients with stage IA malignant melanoma.

2018

We aimed to determine the prevalence and importance of fear of cancer progression (FoP) in melanoma patients with stage IA tumours to assess psychosocial and demographic factors associated with severity of FoP and to determine the relationship of FoP and quality of life (QoL). One hundred and thirty-six patients with stage IA melanoma completed the short version of the Fear of Progression Questionnaire (FoP-Q-SF), the Hospital Anxiety and Depression Scale (HADS) and the EORTC-QLQ-C30. We found a mean FoP-Q-SF sum score of 30.2 points (±8.4 points SD). In this study, 33% of patients reported high FoP at or above the cutoff-value of 34 points. Higher FoP was found in women (p < 0.01), young (…

OncologyAdultMalemedicine.medical_specialtyMedizinAnxietyHospital Anxiety and Depression Scale03 medical and health sciences0302 clinical medicineQuality of lifeRisk FactorsInternal medicinemedicinePrevalenceHumans030212 general & internal medicineStage (cooking)MelanomaDepression (differential diagnoses)AgedAged 80 and overPsychiatric Status Rating Scalesbusiness.industryCancerFearMiddle Agedmedicine.diseasehumanitiesLogistic ModelsOncologyPhobic Disorders030220 oncology & carcinogenesisDisease ProgressionQuality of LifeAnxietyFemaleSkin cancermedicine.symptombusinessPsychosocialEuropean journal of cancer care
researchProduct

Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in S…

2017

ABSTRACT While bivalent and quadrivalent HPV vaccines have been used for about 10 years, a nonavalent vaccine against HPV types 6/11/16/18/31/33/45/52 and 58 has been recently approved by FDA and EMA and is now commercially available. The objective of our study was to evaluate the potential impact of the nonavalent vaccine on HPV infection and related low- and high-grade squamous intraepithelial lesions (LSIL, HSIL), compared to the impact of the quadrivalent vaccine, in a female population living in Sicily (Italy). Low estimates of HPV vaccine impact were calculated as prevalence of HPV 6/11/16/18/31/33/45/52 and 58 genotypes, alone or in association, but excluding presence of other HPV ty…

OncologyAdultmedicine.medical_specialtyReferralGenotypeImmunologyUterine Cervical NeoplasmsHPV vaccinesCervix UteriHospital based study03 medical and health sciences0302 clinical medicineHuman Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18Internal medicinevaccineGenotypemedicinePrevalenceHumansImmunology and Allergy030212 general & internal medicinePapillomavirus VaccinesquadrivalentReferral and ConsultationSicilyFemale populationsquamous intraepithelial lesionGynecologyPharmacologyPotential impactHpv typesbusiness.industryPapillomavirus InfectionsHPV infectionsquamous intraepithelial lesionsvirus diseasesmedicine.diseaseUterine Cervical DysplasiaResearch Papersimpact estimateHPV infection; impact estimate; nonavalent; quadrivalent; squamous intraepithelial lesions; vaccine; Immunology and Allergy; Immunology; Pharmacology030220 oncology & carcinogenesisHPV infectionFemalebusinessnonavalent
researchProduct

Oncology beyond the hospital: 7 years taking care of cancer patients from the very begining until the last consequences.

2017

75 Background: Comprehensive and continuous care is esential for the correct management of cancer patients. To achieve this, specific programs for early diagnosis and long survivor care are needed. Since 2007, within the project “Oncology beyond the Hospital: Oncologic assistance at the Universitary General Hospital of Valencia”, the Oncologist Liaison was created. Methods: Two tracks were designed: High-resolution track for patients with suspicion of non-diagnosed cáncer; and Oncologist Liaison track, to organize the follow-up of cáncer long survivors. We present a descriptive and retrospective study by reviewing medical records of patients referred to the high-resolution diagnostic consu…

OncologyCancer Researchmedicine.medical_specialtybusiness.industryMedical recordPrimary care physicianCancerRetrospective cohort studymedicine.diseaseOncologyInternal medicinemedicineGeneral hospitalbusinessJournal of Clinical Oncology
researchProduct

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, mu…

2013

Contains fulltext : 118365.pdf (Publisher’s version ) (Closed access) BACKGROUND: Until now, only imatinib and sunitinib have proven clinical benefit in patients with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression. We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib. METHODS: We did this phase 3 trial at 57 hospitals in 17 countries. Patients with histologically confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib were rando…

OncologyMaleIndolesPyridinesSettore MED/06 - Oncologia MedicaSU11248MedizinPiperazineslaw.inventionchemistry.chemical_compoundRandomized controlled triallawClinical endpointSunitinibTreatment Failureregorafenib; gastrointestinal stromal tumours; imatinib and sunitinibGastrointestinal Neoplasmseducation.field_of_studyGiSTSunitinibKITAge-related aspects of cancer Quality of hospital and integrated care [ONCOL 2]General MedicineMiddle AgedSurvival RateBenzamidesImatinib MesylateFemaleADJUVANT IMATINIBTYROSINE KINASE INHIBITORColorectal NeoplasmsLife Sciences & Biomedicinemedicine.drugGROWTH-FACTORmedicine.medical_specialtyGastrointestinal Stromal TumorsPopulationMESYLATEAntineoplastic AgentsIMATINIBArticleMECHANISMSMedicine General & InternalDouble-Blind MethodTranslational research [ONCOL 3]General & Internal MedicineRegorafenibInternal medicineMANAGEMENTmedicineHumansPyrroleseducationProtein Kinase InhibitorsAgedScience & TechnologyGASTROINTESTINAL STROMAL TUMOURSimatinib and sunitinibMUTATIONSbusiness.industryPhenylurea CompoundsGIST regorafenib imatinib sunitinib phase III trialSurgeryClinical trialImatinib mesylatePyrimidineschemistryregorafenibbusinessRESISTANCE
researchProduct

Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital.

2008

&lt;i&gt;Objectives:&lt;/i&gt; To investigate the safety and efficacy in terms of PSA response of a low-dose oral combination of estramustine phosphate (EMP) and etoposide (VP16) in hormone- refractory prostate cancer (HRPC) patients. Well-tolerated outpatient chemotherapy regimens for patients unfit and/or unwilling to be admitted to hospital are needed. &lt;i&gt;Methods:&lt;/i&gt; Fifty-six HRPC patients with metastatic disease (median age 75 years) were randomized between arm A (daily oral EMP 10 mg/kg, in 3 doses) and arm B (28-day cycle with low-dose EMP 3 mg/kg once daily plus VP16 25 mg/m&lt;sup&gt;2&lt;/sup&gt; once daily on days 1 through 14). Baseline characteristics between the t…

OncologyMalemedicine.medical_specialtyHormone refractoryOral chemotherapyUrologyUrologyPsa responseAdministration OralAntineoplastic AgentsAdenocarcinomaProstate cancerhormone-refractory prostate carcinoma Oral chemotherapyInternal medicinemedicineEstramustine phosphateHumansEtoposideAgedEtoposideAged 80 and overbusiness.industryProstatic NeoplasmsProstate carcinomaMiddle Agedmedicine.diseaseHospitalizationEstramustinePatient Compliancebusinessmedicine.drugHormoneUrologia internationalis
researchProduct

PI3K/AKT Activation and Response in Phase IB: AKT Inhibitor GDC-0068 with Docetaxel (D) Or MFOLFOX6 (F) in Refractory Solid Tumors

2013

R. Meng1, L. R. Molife2, L. de Mattos-Arruda3, A. Hollebecque4, S. J. Isakoff5, D. Roda6, Y. Yan1, A. Cervantes6, J. C. Soria4, J. Mateo2, G. Argiles3, J. C. Bendell7 Genentech, South San Francisco, CA, USA, Institute of Cancer Research/ Royal Marsden Hospital, Sutton, United Kingdom, Vall d’Hebron University Hospital, Barcelona, Spain, Institut Gustave Roussy, Villejuif, France, Massachusetts General Hospital, Boston, MA, USA, Institute of Health Research INCLIVA, University of Valenica, Valencia, Spain, Sarah Cannon Research Institute, Nashville, TN, USA

OncologySolid tumourmedicine.medical_specialtybusiness.industryHematologyAkt inhibitorUniversity hospitalInstitut Gustave RoussyOncologyDocetaxelInternal medicinemedicineGeneral hospitalbusinessProtein kinase BPI3K/AKT/mTOR pathwaymedicine.drugAnnals of Oncology
researchProduct

The management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14…

2014

T. Seufferlein1, J. L. Van Laethem2, E. Van Cutsem3*, J. D. Berlin4, M. Buchler5, A. Cervantes6, K. Haustermans3, M. Hidalgo7, E. M. O’Reilly8, C. Verslype3, W. Schmiegel9 & P. Rougier10 Department of Internal Medicine I, University of Ulm, Ulm, Germany; Department of Gastroenterology, Hopitaux Universitaires Bordet-Erasme, Brussels; Digestive Oncology and Radiation Oncology, University Hospitals and KU Leuven, Leuven, Belgium; Department of Medicine, Vanderbilt University, Nashville, USA; Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany; Department of Hematology and Medical Oncology, INCLIVA, University of Valencia, Valencia; Gastro…

Oncologymedicine.medical_specialtyTransplantation surgerybusiness.industryGeneral surgeryHematologyGastrointestinal systemUniversity hospitalmedicine.diseasehumanitiesLocally advanced pancreatic cancerOncologyInternal medicineRadiation oncologymedicineGastrointestinal cancerbusinessAnnals of Oncology
researchProduct

Endocrine tumours: epidemiology of malignant digestive neuroendocrine tumours.

2013

Little is known about patients with malignant digestive neuroendocrine tumours (MD-NETs). Although their incidence is increasing, MD-NETs remain a rare cancer, representing 1% of digestive cancers. Most MD-NETs are well-differentiated. MD-NET poorly differentiated carcinomas account for 20% of cases on average. Anatomical localisation of MD-NETs varied according to geographic region. Stage at diagnosis and prognosis for patients with MD-NETs in the general population are considerably worse than often reported from small hospital case series. Prognosis varies with tumour differentiation, anatomic site and histological subtype. There are significant differences in survival from MD-NETs among …

Oncologymedicine.medical_specialtyeducation.field_of_studybusiness.industryEndocrinology Diabetes and MetabolismPoorly differentiatedIncidence (epidemiology)PopulationGeneral MedicineRare cancerSmall hospitalNeuroendocrine TumorsEndocrinologyEndocrinologyInternal medicineEpidemiologyEndocrine Gland NeoplasmsmedicineEndocrine systemAnimalsHumansbusinesseducationDigestive cancerGastrointestinal NeoplasmsEuropean journal of endocrinology
researchProduct